Physician profile
Brian Masterson
NPI 1053522359
$3,875.04
in general payments reported to CMS, 2019-2025
35 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $393 · 2021: $985 · 2022: $739 · 2023: $725 · 2024: $54.69 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.96 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $483.97 | 2019-2025 | Trintellix |
| Lundbeck LLC | $419.50 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $409.39 | 2019-2023 | Austedo |
| Abbott Laboratories | $387.49 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $263.48 | 2019-2023 | Ingrezza |
| Allergan, INC. | $186.66 | 2019 | |
| Amarin Pharma, INC. | $140.54 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $135.84 | 2019-2021 | |
| Novo Nordisk INC | $118.32 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.14 | 2022-2023 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $91.03 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $63.51 | 2019-2020 | |
| Shire North American Group INC | $55.42 | 2019 | |
| Merck Sharp & Dohme LLC | $43.95 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.95 | 2020-2021 | |
| Noven Therapeutics, LLC | $28.69 | 2023 | Xelstrym |
| Neos Therapeutics, Lp | $28.19 | 2023 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $27.27 | 2025 | Auvelity |
| Edwards Lifesciences Corporation | $23.46 | 2021 | |
| Amgen INC. | $20.93 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.50 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $20.22 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.42 | 2022 | |
| Genentech USA, INC. | $18.14 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.84 | 2019 | |
| Ibsa Pharma INC. | $15.57 | 2021 | |
| Dexcom, INC. | $15.03 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.00 | 2025 | Qelbree |
| Esperion Therapeutics, INC. | $14.27 | 2021 | |
| Eisai INC. | $13.75 | 2022 | |
| Agile Therapeutics, INC. | $13.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.31 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Masterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.